



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/809,060	03/16/2001	Carl T. Wild	1900.0260001/JMC/CML

O I P E J C 2  
JUL 22 2005  
PATENT & TRADEMARK OFFICE

STERNE, KESSLER, GOLDSTEIN & FOX PLLC  
 1100 NEW YORK AVENUE, N.W.  
 WASHINGTON, DC 20005

CONFIRMATION NO. 4671  
 FORMALITIES LETTER



\*OC000000016352360\*

Date Mailed: 06/23/2005

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
 Commissioner for Patents  
 P.O. Box 1450

Alexandria VA 22313-1450

---

*A copy of this notice **MUST** be returned with the reply.*

*J. Decker*

Office of Initial Patent Examination (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Robert Greene Sterne  
 Edward J. Kessler  
 Jorge A. Goldstein  
 David K.S. Cornwell  
 Robert W. Esmond  
 Tracy-Geni G. Durkin  
 Michele A. Cimbala  
 Michael B. Ray  
 Robert E. Sokohl  
 Eric K. Steffe  
 Michael Q. Lee  
 Steven R. Ludwig  
 John M. Covert  
 Linda E. Alcorn  
 Robert C. Millonig  
 Donald J. Featherstone  
 Timothy J. Shea, Jr  
 Michael V. Messinger  
 Judith U. Kim

Patrick E. Garrett  
 Jeffrey T. Hevey  
 Heidi L. Kraus  
 Eldora L. Ellison  
 Thomas C. Fria  
 Albert L. Ferro\*  
 Donald R. Banowitz  
 Peter A. Jackman  
 Teresa U. Medler  
 Jeffrey S. Weaver  
 Kendrick P. Patterson  
 Vincent L. Capuano  
 Brian J. Del Buono  
 Virgil Lee Beaston  
 Theodore A. Wood  
 Elizabeth J. Haanes  
 Joseph S. Ostroff  
 Frank R. Cottingham  
 Christine M. Uhlir

Rae Lynn P. Guest  
 George S. Bardmessner  
 Daniel A. Klein  
 Jason D. Eisenberg  
 Michael D. Specht  
 Andrea J. Kamage  
 Tracy L. Muller  
 Jon E. Wright  
 LuAnne M. DeSantis  
 Ann E. Summerfield  
 Aric W. Ledford  
 Helene C. Carlson  
 Cynthia M. Bouchez  
 Timothy A. Doyle  
 Gaby L. Longsworth  
 Lori A. Gordon  
 Nicole D. Detar  
 Ted J. Ebersole  
 Laura A. Vogel

Michael J. Mancuso  
 Bryan S. Wade  
 Aaron L. Schwartz  
 Michael G. Penn\*  
 Shannon A. Carroll\*  
 Wesley W. Jones\*  
 Matthew E. Kelley\*  
 Nicole R. Kramer\*

**Registered Patent Agents**

Karen R. Markowicz  
 Nancy J. Leith  
 Matthew J. Dowd  
 Katrina Yuijan Pei Quach  
 Bryan L. Shelton  
 Robert A. Schwartzman  
 Teresa A. Colella  
 Jeffrey S. Lundgren  
 Victoria S. Rutherford

Michelle K. Holoubek  
 Simon J. Elliott  
 Julie A. Heider  
 Mita Mukherjee  
 Scott M. Woodhouse  
 Christopher J. Walsh  
 Lilianna Di Nola-Baron  
 Peter A. Socarras  
 Jeffrey Mills

**Of Counsel**

Kenneth C. Bass III  
 Evan R. Smith  
 Marvin C. Guthrie

\*Admitted only in Maryland  
 +Admitted only in Virginia  
 •Practice Limited to  
 Federal Agencies

July 22, 2005

**WRITER'S DIRECT NUMBER:**  
 (202) 772-8610

**INTERNET ADDRESS:**  
 SELLIOTT@SKGF.COM

Commissioner for Patents  
 PO Box 1450  
 Alexandria, VA 22313-1450

**Art Unit 1648**

**Attn: Mail Stop Missing Parts**

Re: U.S. Utility Patent Application  
 Appl. No. 09/809,060; Filed: March 16, 2001  
 For: **A Method for Generating Immunogens that Elicit Neutralizing Antibodies Against Fusion-Active Regions of HIV Envelope Proteins**  
 Inventors: WILD *et al.*  
 Our Ref: 1900.0260001/JMC/SJE

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a);
3. 33 pages of the Substitute Sequence Listing;
4. Computer readable copy of the Substitute Sequence Listing; and
5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
July 22, 2005  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Simon J. Elliott  
Attorney for Applicants  
Registration No. 54,083

JMC/SJE/lam  
Enclosures

423729.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Carl T. Wild *et al.*

Appl. No.: 09/809,060

Filed: March 16, 2001

**For: A Method for Generating  
Immunogens that Elicit  
Neutralizing Antibodies Against  
Fusion-Active Regions of HIV  
Envelope Proteins**

Confirmation No.: 4671

Art Unit: 1648

Examiner: Lucas, Zachariah

Atty. Docket: 1900.0260001/JMC/SJE

**Submission of Substitute Sequence Listing  
Under 37 C.F.R. § 1.825(a)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated June 23, 2005, Applicants submit herewith a substitute sequence listing in compliance with 37 C.F.R. § 1.825(a).

***In the Specification:***

Please cancel the existing Sequence Listing for the above-identified application, replace it with the substitute Sequence Listing appended hereto, and insert the same at the end of the application.

***Remarks***

In the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated June 23, 2005, the Office asserts that Applicants have not submitted a paper copy of the sequence listing in compliance with 37 C.F.R. § 1.821, or a statement that the paper copy was identical to the disk copy. Applicants respectfully disagree, as paper and disk copies were submitted to the Office on September 16, 2003, in full compliance with the requirements under 37 C.F.R. §§ 1.821-1.824. Accordingly, the present filing is a submission of a substitute sequence listing under 37 C.F.R. § 1.825.

This submission does not include new matter. 37 C.F.R. § 1.825(a). In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Substitute Sequence Listing and the computer readable copy of the Substitute Sequence Listing submitted herewith are the same.

It is respectfully believed this application is now in condition for examination. Early notice to this effect is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Simon J. Elliott, Ph.D.  
Agent for Applicants  
Registration No. 54,083

Date: July 22, 2005

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

417171\_1.DOC